ISSUE #11 ยท TUESDAY, 6 OCTOBER 2026
The Bareja Brief B logo

The Bareja Brief

Fifteen stories, five topics, under 10 minutes. Every day at 8:30 AM, in your inbox. No fluff.

Subscribe to the Brief

03Vaxcyte reports mixed comparator results in vaccine trial

Vaxcyte reported Phase III results for its 31-serotype pneumococcal vaccine candidate VAX-31 on Monday. In 3,572 adults, it met non-inferiority criteria for all 20 serotypes shared with Prevnar 20, but 17 of 19 shared with Capvaxive. The company plans a US regulatory filing.

Clinical Trials Arena โ†—
SUBSCRIBE

Get The Bareja Brief every morning

New readers choose five topics and confirm by email. Already subscribed? Request a private link to change your choices.